Beckley Psytech Announces First Cohort of Psychotherapists Have Begun Training for Treatment Resistant Depression Phase 2 Trials

January 24, 2022 2:00 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
  • Training programme to be conducted in partnership with industry-leading educational company, Fluence
  • Initiation of training represents key step to incorporate psychedelic-assisted psychotherapy to deliver potentially clinically meaningful improvements

 

OXFORD, England--(BUSINESS WIRE)-- Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that the first cohort of psychotherapists have begun training in advance of the expected Phase 2 clinical trial examining 5-MeO-DMT-assisted psychotherapy in treatment resistant depression (TRD). The training is being conducted in collaboration with Fluence, an expertise-driven educational platform that provides professional training in psychedelic therapy for psychiatrists, psychotherapists, social workers, and other healthcare practitioners.

The initial elements of the training programme feature online, interactive, self-taught modules, after which participating psychotherapists will be hosted by the Kadima Neuropsychiatry Institute in San Diego, U.S. where the trainers will provide live, in-person training sessions. This comprehensive training programme aims to empower psychotherapists to deliver meaningful change to people suffering from severe mental health disorders and provide patients a best-in-class psychotherapy framework inside and outside of the clinic. Over the course of the next year Beckley Psytech aims to train 80 psychotherapists.

Psychedelic-assisted psychotherapy works to create a therapeutic model which improves clinical symptoms and promotes lasting, positive change for patients. Through this partnership with leading psychiatrists and researchers, Beckley Psytech aims to develop a holistic system which will enable delivery of the best care to patients.

Cosmo Feilding Mellen, CEO of Beckley Psytech, said: “The initiation of this training programme is a vital step towards developing an ecosystem to support the emerging paradigm shift in how we treat neurological and psychiatric conditions. We are delighted to be partnered with Fluence, a world-class leader in psychotherapy training and education, and we are confident that this programme will deliver a differentiated solution to optimise patient outcomes in difficult-to-treat medical conditions.”

Frederick Reinholdt, participating psychotherapist, commented, "What a fortunate opportunity to meet up with such a wide range of clinicians and researchers all with a keen interest in the therapeutic potential 5-MeO-DMT may prove to possess. In partnership with Fluence, Beckley Psytech has devised a rich and leading-edge training program."

Dr David Feifel, Director of the Kadima Neuropsychiatry Institute, said, “The impetus to offer Kadima’s space and facilitate the training is merely our desire to facilitate the success of this exciting and important project and to develop a deeper collaborative relationship.”

Dr. Elizabeth Nielson, Fluence co-founder "Due to the unique demands of creating and testing a psychedelic-assisted psychotherapy with 5-MeO-DMT, our focus on psychotherapy and psychotherapist training at Fluence is a natural fit for Beckley Psytech’s innovative research program. It’s been a delight to see clinicians get involved and learn Beckley Psytech’s therapeutic approach and protocol so they’re ready to provide this therapy to study participants."

Beckley Psytech is currently conducting a double-blind, randomised, single ascending dose Phase 1 study to evaluate the safety and tolerability of a single intranasal dose of Beckley Psytech's novel formulation of intranasal 5-MeO-DMT healthy subjects.

Beckley Psytech - www.beckleypsytech.com
Beckley Psytech is a clinical stage privately held company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a broad pipeline of psychedelic compounds in rare and more common diseases. Our vision is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients with high unmet medical need around the world, suffering from Short-lasting unilateral neuralgiform headache attacks (SUNHA), treatment resistant depression and other profoundly debilitating conditions. Beckley Psytech was founded in 2019 leveraging some of the expertise developed over more than 20 years by the Beckley Foundation, an independent non-profit and world leader in psychedelic medicine research, and is based out of Oxford, United Kingdom.

About Fluence https://www.fluencetraining.com
Fluence is an expertise-driven educational platform that provides professional training in psychedelic therapy and psychedelic integration for psychiatrists, psychotherapists, social workers, and other healthcare practitioners. Fluence’s mission is to give healthcare providers the clinical skills and knowledge to provide effective, compassionate, evidence-based psychedelic therapy and integration services to patients through dynamic, interactive online and in-person trainings.

Beckley Psytech
Cosmo Feilding Mellen
Chief Executive Officer
[email protected]

Communications
FTI Consulting
Ben Atwell / Mike Trace

+44 (0)20 3727 1000
[email protected]

Investor Relations
LifeSci Advisors
Guillaume van Renterghem

+41 76 735 01 31
[email protected]

Source: Beckley Psytech



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Business Wire, Press Releases